Research Abstract Database 
Hematology and Oncology TGFB signature at 2 weeks to predict response to preoperative therapy (PT) with bevacizumab (B) and chemotherapy (CT) in early breast cancer (EBC)
Hematology and Oncology TGFB signature at 2 weeks to predict response to preoperative therapy (PT) with bevacizumab (B) and chemotherapy (CT) in early breast cancer (EBC)
Research Abstract Database
| Research Abstract Database | Search |
TGFB signature at 2 weeks to predict response to preoperative therapy (PT) with bevacizumab (B) and chemotherapy (CT) in early breast cancer (EBC) |
|
Author: Williams, Nicole Author's Email: nicole.williams2@uhhospitals.org Mentor: Harris, Lyndsay Mentor's Email: Lyndsay.Harris@uhhospitals.org Project Type: basic research Keyword: properative, chemotherapy, breast cancer, bevacizumab, gene sequencing, response to treatment Author's Position: fellow Year Presented: 2021 |
 | |
